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Small cell bladder carcinoma is a rare
and frequently fatal disease. It can be
distinguished from classical urothelial carcinoma micro-
scopically and immunohistochemically. Small cell bladder
carcinoma has histologically similar properties with other
small cell carcinomas in other organs. It has a worse prog-
nosis when compared to urothelial bladder cancer.
Multimodal treatments are recommended although there is
no widely accepted consensus regarding to the treatment
algorithm because of its rarity. In this review, clinical prop-
erties and diagnosis of small cell bladder carcinoma, its
histopathological and immunohistochemical properties and
treatment modalities are examined.
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develops from cells of the same origin. There are two dif-
ferent theories regarding to the origin of the cells.
According the first theory, amine precursor uptake and
decarboxylation (APUD) cells take origin from neural crest
and migrate to different epithelial areas in the body. APUD
cells present intracytoplasmic neurosecretory granules and
can be positively stained with chromogranin A (CGA).
According the second theory, clonality studies have shown
that NET is originated from multipotent root cells that can
be converted in different tissue types. Thus cancers have
similar molecular abnormalities.
EPIDEMIOLOGY
Bladder carcinoma (BC) is the fourth most frequent can-
cer in men and is responsible for 14,000 cancer-related
deaths in United States of America annually (2). 90% of
BC is urothelial carcinoma and the most frequently types
out of urothelial carcinoma are squamous cell carcinoma
and adenocarcinoma (2, 3). SmCC is a rare form of BC
and responsible for < 1% of primary BC (3). SmCC is fre-
quently seen in men in seventh or eighth decade
(1, 4, 5). Its incidence between 1991 and 2005 in United
States of America has increased from 0.05 to 0.14 in
100.000 inhabitants (3). In men, it is observed as 3 times
more than women and in white race, it is observed as 10
times more than the other-than-white races (3). It is
more frequent in advanced age and average incidence
age is 71 years (4-6). Smoking is considered to be a risk
factor and smoking history is present in 50-70% of
SmCC patients (7). In most of the patients, there are
non-specific risk factors such as bladder stone, bladder
manipulation and chronic cystitis (4, 5, 7). Exposure to
second-hand smoking and chemicals is controversial (7). 
CLINICAL PROPERTIES AND DIAGNOSIS
SmCC BC is similar to bladder urothelial carcinoma in
terms of age of onset, gender and symptoms. It presents
with local, systemic or paraneoplastic symptoms. The
most frequent symptom is painless gross hematuria that
is observed in 80-90% (1, 4, 7, 8). Dysuria, obstructive
voiding symptoms, abdominal pain, pelvic pain and
recurrent urinary tract infection are other frequently
observed symptoms. Sometimes it may also occur with
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INTRODUCTION
Neuroendocrine tumors (NET) are a heterogeneous
group of tumors that developed from neuroendocrine
cells. They are separated in sub categories according to
the organs from which they originate. NET was first
described in the bronchopulmonary tract by Barnard in
1926 (1). Small cell carcinoma (SmCC) is developed
from the lower respiratory tract and spreads out rapidly
and is common in chronic smokers. SmCC may develop
in extrapulmonary regions and its diagnostic criteria are
the same as in pulmonary SmCC. Uniform small cells
with scant cytoplasm, salt-pepper like chromatin and
inconspicuous nucleoli are the diagnostic findings. 
Extrapulmonary NET can develop from almost every part
of the body except central nervous system. Primary loca-
tion can be esophagus, gastrointestinal tract, pancreatobil-
iary system, larynx, salivary glands, uterus, cervix uteri,
vagina, bladder, prostate, breast, lacrimal gland and der-
mis. In urinary system, NET was firstly described by
Resnick in 1966 as a carcinoid subtype in the kidney
whereas 1977, Wenk described NET with SmCC subtype
in the prostate. Regarding to bladder, Cramer has first
described NET in 1981 with a sub-type of SmCC (1).
Today in the urinary system, NET is most frequently
observed in the bladder, then prostate, kidneys and ureter
respectively (1). NET, both pulmonary or extrapulmonary,
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systemic symptoms such as weight loss and fatigue. It
can rarely present by a paraneoplastic syndrome
although less frequently when compared to pulmonary
SmCC. Paraneoplastic syndrome may cause hypercal-
cemia, hypophosphatemia, Cushing syndrome and sen-
sorial neuropathy (9, 10). 
SmCC and urothelial BC cannot be definitely differenti-
ated via imaging methods. Computerized tomography
(CT) of urothelial carcinoma shows in 70-80% a focal
asymmetric bladder wall thickening occurs and in 20%
the muscle invasive carcinoma is demonstrated as a soli-
tary mass (11). At CT, SmCC presents as large solitary
lesion consisting of necrosis and calcifications at different
ratios. Frequently, diffuse bladder wall thickening is seen
and extension to perivesical fat and surrounding tissues
occurs (11).
Diagnosis is made by cystoscopy and microscopic evalu-
ation of the tissue obtained via transurethral resection of
bladder tumor (TUR-BT). Macroscopically it presents as
a polypoid mass from 1,5 to 13 cm large (4, 11, 12).
Despite most of the tumors are located on the lateral wall
of the bladder, they may less often located on the base,
trigon, anterior wall and fornix of the bladder (1, 4, 8).
Lesional cells can be observed in the urine cytology (13).
Histopathological and immunohistochemical assessment
Microscopically SmCC BC is similar to SmCC in other
organs and classification is performed according to the
World Health Organization (WHO) classification system.
Although tumor occurs as a diffuse growth without pat-
tern, sometimes focal nests and trabecula can be seen
(14). Nests are formed of small or medium-size cells.
Cells are formed by round oval overlapping nuclei and
regularly distributed salt-and-pepper like chromatin and
inconspicuous nucleoli (14). Cytoplasm of the cells is
scarce and organelles are rare. Frequently mitosis, crush
artifact and geographical necrosis are seen. Azzopardi
effect (crush artifact) is the indicator of high proliferation
ratio. Electron microscopy shows the presence of mem-
brane-limited dense core granules with a diameter of
150-250 mm (9). 
Bladder SmCC is in mixed type more frequently when
compared to pulmonary. It is 40-70% mixed and most
frequently is accompanied to urothelial carcinoma
(13, 15). According to their frequency, it may be accom-
panied also to squamous cell carcinoma, adenocarcino-
ma and rarely sarcomatoid carcinoma (15). Prognosis of
mixed tumors, even if SmCC is present in a small focal
area, is similar to the bad prognosis of pure SmCC
(8, 16). Thus it should be always demonstrated whether
there is presence SmCC in classical urothelial carcinoma
or not. 
In case of rarely seen diagnostic difficulties, immunohis-
tochemical staining may be applied to verify the diagno-
sis. Thus synaptophysin, CGA, neuron specific enolase
(NSE), CD56 and similar staining can be applied
although their sensitivity for bladder SmCC is relatively
low (15). Independent morphologic appearance of blad-
der SmCC should be sufficient according to WHO diag-
nosis criteria (13).
CGA is also known as parathyroid secretory protein 1
and coded by the CHGA gene. Because it is related to the
release of amine/peptide, CGA is expressed from β cells
of pancreas in the cells similar to enterochromaffin and
in chromaffin cells although it is not present in steroid
hormone producing cells (13). It is the neuroendocrine
marker for bladder SmCC with the lowest sensitivity and
it is stained with a one-third to one-half ratio (15). A 5%
positivity is observed in urothelial bladder carcinoma
(17). Synaptophysin is known as the major synaptic vesi-
cle protein p38 and coded by the SYP gene. It is present
in all the cells producing amine/peptide and steroid hor-
mone and in all the neurons (13). CD56 is known as the
neural cell adhesion molecule and coded by the NCAM1
gene. It is present in the membrane of neurons, glia,
skeletal muscles and natural killer cells (13). For bladder
SmCC, the sensitivity of synaptophysin and CD56 is
higher than CGA. In a study of Buza et al., they have
found sensitivity of CD56 as 71.4% and suggested that it
is the most sensitive marker for the bladder SmCC (18).
In the same study, sensitivities of synaptophysin and
CGA are found as 64.3% and 28.6% respectively (18).
NSE is known as γ-enolase or enolase 2 and coded by the
ENO2 gene. It shows phosphopyruvate hydratase activi-
ty and is present in mature neuron cells. Its sensitivity for
bladder SmCC is about 80% and its specificity is very
low (14, 18, 19).
Thyroid transcription factor 1 (TTF-1) is known as NK2
homeobox 1 and coded by the NKX2-1 gene. It is the
transcription factor that is produced in thyroid follicular
cells, Clara cells and type 2 pneumocytes in the lungs
and diencephalon in the brain (13). Cheuk et al. have
found the sensitivity of TTF-1 for extrapulmonary SmCC
as 42% (20). Jones et al. have observed TTF-1 positivity
in the bladder SmCC in 50% (21). No relationship
between TTF-1 expression and the prognosis of bladder
SmCC is found (21). Thus it is not reliable for the diag-
nosis of primary SmCC and there is no prognosis antici-
pation.
The p53 is coded by the TP53 gene and it is a tumor sup-
pressor protein. Various cancers are developed by the
mutation of p53 and these generally progress by poor
prognosis. A p53 overexpression in bladder SmCC is
seen between 37 and 80% (13, 14). No relationship
between p53 overexpression and the prognosis of blad-
der SmCC is found (14).
The p16 is known as cycline-dependent kinase inhibitor
2A and coded by the CDKN2A gene (13). It takes place
in the regulation of p16 cell cycle and various cancers
develop by the p16-retinoblastoma pathway in its muta-
tions. Normal tissues and normal urothelial mucosa has
heterogeneous staining pattern with p16 and is positive
in 1-10% (22). In the study of Buza et al. in which they
have taken 10% as the limit value for abnormal p16
staining, they have found p16 positivity as 92.8 in blad-
der SmCC and as 43.7 in high-grade urothelial carcino-
ma (18). This data shows that the changes in p16-
retinoblastoma pathway are required for the develop-
ment of bladder SmCC.
The p63 is known as the transformation-related protein
63 and coded by the TP63 gene (13). It is a member of
p53 family and it features as a transcription factor. The
p63 activity is different between the bladder SmCC and
high-grade urothelial carcinoma. While p63 is found
negative in 92.8% of the patients with bladder SmCC, it
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is found positive in 81.3% of the patients with urothelial
carcinoma (18). Thus p63 is an immunohistochemical
marker that may help to differentiate the bladder SmCC
and urothelial carcinoma.
Various cytokeratin stains were also studied in bladder
tumors. CK20 expression shows that tumor aggressive-
ness is low. While Buza et al. found the CK7 positivity as
64.3% in the bladder SmCC, CK20 was only stained
focally in 2 cases (18). In bladder SmCC, CAM 5.2 is
found positive in 60-70%, 34βE12 in 40-45% and
epithelial membrane antigen as 75-80% (4, 5, 13-15, 17,
18, 20, 21).
Uroplakin is a urothelium-specific transmembrane pro-
tein and it is a terminal urothelial cytodifferentiation
marker. Despite it is positive at various ratios in the blad-
der urothelial carcinoma, Jones et al. have found it nega-
tive in all 44 patients with SmCC (21). There are also
studies regarding to the c-kit that is a transmembrane
tyrosine kinase receptor and proto-oncogene (CD117)
and also human epidermal growth factor receptor 2
(Her2/neu) with positivity between 30 and 50% is found
(10). Positivity of these two markers may be important in
terms of treatment and prognosis in the future.
In the diagnosis of bladder SmCC, the differentiation
between poor differentiated urothelial carcinoma, alveo-
lar rhabdomyosarcoma, lymphoma, lung SmCC metasta-
sis and spreading of SmCC of adjacent organs should be
done. Immunohistochemical studies help for the differ-
ential diagnosis instead of diagnosis. In prostatic SmCC,
prostate-specific antigen is frequently negative and it
does not assist in the differentiation of bladder SmCC. In
prostatic SmCC, p501s and prostate membrane antigen
is low (approximately 20%) positive. Although the deter-
mination of TMPRSS2-ERG gene fusion establishes the
diagnosis of prostatic SmCC, it does not exclude the pro-
static origin (13). Alveolar rhabdomyosarcomas may not
show the classical alveolar structure and they help posi-
tive staining by myogenin, MyoD1 and desmine that
show muscle differentiation (10, 13). Non-Hodgkin lym-
phoma is differentiated from bladder SmCC because of
positive CD45 and negative CK (10). 
STAGING AND TREATMENT
In simple staging used for lung SmCC, the disease is
divided in “limited” and “extensive” (10). Limited disease
consists of a single radiotherapy port or operation area.
In 2007, International Association for the Study of Lung
Cancer group has recommended tumor-node-metastasis
(TNM) staging for lung SmCC because it is well related
to the prognosis of the patients (10). According to our
own experiences, TNM staging for bladder SmCC is bet-
ter in the suggestion of prognosis. As in the bladder
tumors, thorax and abdomen CT are standard approach-
es for staging. Because magnetic resonance imaging
shows the distribution of local disease better than CT,
Moretto et al. recommend it in the patients for whom rad-
ical cystectomy is planned (10). Due to the risk of lymph
nodes, liver and bone metastasis and less often of lung
and brain metastasis of the disease, some clinicians also
recommend 99mTc-MDP bone scanning and 18F-FDG
positron emission tomography (9, 10). CT-urography for
demonstration of filling defect in the urinary tract is con-
troversial (10, 11).
Multimodal approach is suggested in the treatment (9,
10). Because it is a rarely-seen disease, there is no treat-
ment scheme (guideline) except that of the Canadian
Association of Genitourinary Medical Oncologists (9, 10),
but they refers to the results of a single center retrospec-
tive study and their evidence and suggestion levels are
low. While surgery, surgery and adjuvant or neoadjuvant
chemotherapy and surgery and/or chemotherapy can be
applied for the limited disease, only chemotherapy can
be applied in extensive diseases.
Individual surgery options are radical cystectomy and
TUR-BT. Simple TUR-BT treatment is an insufficient
option for the disease control due to high recurrence
ratio and a survival period of 3-6 months (9, 23).
However, if the general status of the patient does not per-
mit any other treatment modality, it can be applied in
this limited patient group. Cheng et al. cannot find 5-year
survival difference between the patients with and with-
out individual radial cystectomy (%15 vs. %18, p = 0,65)
(4) although Choong et al. have shown a 5-year survival
in the patients to whom individual radical cystectomy
was applied of 63.6% (12). These studies have shown
that surgery alone, even if radical cystectomy is applied,
does not extend survival in the patients except in select-
ed ones. The combination of surgery and neoadjuvant
chemotherapy increases long-term survival ratios. In fact
bladder SmCC is a systemic disease, even if not initially
demonstrated, and its cells respond to platinum-based
chemotherapies. The more frequently used chemothera-
py protocol is a 3-week cycle including intravenous
etoposide 100 mg/m2 dose on 1st-3rd day and intra-
venous cisplatin 70-100 mg/m2 on the 1st day (24, 25).
Carboplatin may be changed with cisplatin due to its
better toxicity profile. It is argued that the disease is
down-staged by preoperative chemotherapy and that
chemosensitive micro metastases are treated and accord-
ingly the survival periods could be increased. When
Siefker-Radtke et al. have compared patients treated with
radical cystectomy after preoperative chemotherapy to
those treated with radical cystectomy alone, they found
that the 5-year survival period was 78% and 36% respec-
tively (26). Siefker-Radtke et al. have determined in
another study that pathologic downstaging was present
in 78% of the patients via neoadjuvant chemotherapy
and median overall survival was 58 months (24). The
results of Lynch et al. about neoadjuvant chemotherapy
are more dramatic. In their study, radical cystectomy
after neoadjuvant chemotherapy and radical cystectomy
alone and adjuvant chemotherapy after radical cystecto-
my were compared. In the patients to whom radical cys-
tectomy had been applied after neoadjuvant chemother-
apy, median survival was found as 159.5 months and 5-
year survival was found as 79% (25). The results of the
other arms of the study were similar to the literature. In
short, neoadjuvant chemotherapy and radical cystecto-
my in the patients who are suitable for surgery seems to
be the gold standard treatment. 
Application of radiotherapy and surgery and/or
chemotherapy is a bladder-protective method and can be
an alternative to cystectomy. Chemoradiotherapy can be
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applied simultaneously or successively. Lohrisch et al.
reported a 44% 5-year survival in 10 patients after
chemoradiotherapy (9). Bex et al. obtained a complete
response in 88% of 17 patients via chemoradiotherapy
after TURBT and median overall survival was found as
32.5 months. The 5-year survival was calculated as 36%
(27). Trimodal approach can be applied as an alternative
method in the patients who are not suitable for operation
or who do not want radical cystectomy and especially in
the patients with low performance status. 
At the time of diagnosis, prognosis of metastatic SmCC is
poor and median survival is between 5 and 13 months
(8, 16, 27). Platin-based chemotherapy regime is the
standard treatment (8, 12, 16, 26). As an alternative
regime, iphosphamide-doxorubicin can be used and as
single agent, also paclitaxel and irinotecan can be used
(8, 12, 26). Despite it is chemosensitive, overall survival
is relatively poor. When the disease relapse is observed
after the treatment, the same induction regime can be
applied by considering the response to the first treatment
and the disease-free interval. Otherwise second-line
chemotherapy regimes can be used and, as a single
agent, topetecan or vinorelbine can be used (28). As a
combination, CAV (cyclophosphamide, doxorubicin,
vincristine) regime can be used (28). Response ratios to
the second-line regimes are variable. Radiotherapy can
be used as palliative in the patients who have sympto-
matic bone metastasis or brain metastasis. 
Although there are some clinicians recommending pro-
phylactic cranial radiotherapy due to the combination of
advanced stage disease and brain metastasis, there is no
exact data regarding to its efficiency (9). Prognosis of the
patient is related to his performance status and the
spreading of the disease at the time of diagnosis. No rela-
tion is found between the age, gender, symptoms of the
patient and p53 and prognosis (8, 9, 13). Histologically
the patients with pure SmCC can have poorer prognosis
than the patients with mixed SmCC (16).
CONCLUSION
Bladder small cell carcinoma is biologically an aggressive
tumor and it is in most of cases in the advanced or
metastatic stage at the time of diagnosis. Diagnosis can
be easily made by microscopic examination. 
Immunohistochemical stainings are supportive for diag-
nosis. Its prognosis is poor and multimodal approach is
recommended in the treatment. It is important to refer
the patients to centers with experience of multimodal
treatment. In limited disease, radical cystectomy after
platinum-based adjuvant chemotherapy seems to be the
best treatment method. 
In extensive diseases, chemotherapy is the primary treat-
ment. Studies explaining the molecular pathogenesis are
needed and will be instructive for the diagnosis and
treatment of the disease.
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